Skip to main content Back to Top
Advertisement

5/27/2020

Tobramycin Sulfate Lyophilized Powder for Solution

Products Affected - Description

    • Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 63323-0303-51
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 1 count, NDC 39822-0412-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 39822-0412-06

Reason for the Shortage

    • Fresenius Kabi has tobramycin lyophilized powder on shortage due to increased demand.
    • X-Gen did not provide a reason for the shortage.

Estimated Resupply Dates

    • Fresenius Kabi has tobramycin 1.2 gram vials on back order and the company estimates a release date of early-June 2020. Check wholesalers for inventory.
    • X-Gen has tobramycin 1.2 gram vials on back order and the company estimates a release date of early- to mid-June 2020.

Updated

Updated May 27, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 25, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.